[go: up one dir, main page]

WO2006027468A3 - Epitopes t cd4+ du vih restreints a hla-dp4 et leurs applications - Google Patents

Epitopes t cd4+ du vih restreints a hla-dp4 et leurs applications Download PDF

Info

Publication number
WO2006027468A3
WO2006027468A3 PCT/FR2005/002152 FR2005002152W WO2006027468A3 WO 2006027468 A3 WO2006027468 A3 WO 2006027468A3 FR 2005002152 W FR2005002152 W FR 2005002152W WO 2006027468 A3 WO2006027468 A3 WO 2006027468A3
Authority
WO
WIPO (PCT)
Prior art keywords
vih
hla
restricted
epitopes
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/002152
Other languages
English (en)
Other versions
WO2006027468A2 (fr
Inventor
William Cohen
Sandra Pouvelle-Moratille
Gaetan Munier
Bernard Maillere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Publication of WO2006027468A2 publication Critical patent/WO2006027468A2/fr
Publication of WO2006027468A3 publication Critical patent/WO2006027468A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente Invention est relative à des peptides antigéniques du virus de l'immunodéficience humaine (VIH) comprenant au moins un épitope T CD4+ qui est restreint à une molécule HLA-DP4, et à leurs applications vaccinales et diagnostiques.
PCT/FR2005/002152 2004-08-27 2005-08-26 Epitopes t cd4+ du vih restreints a hla-dp4 et leurs applications Ceased WO2006027468A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0409140 2004-08-27
FR0409140A FR2874612A1 (fr) 2004-08-27 2004-08-27 Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications

Publications (2)

Publication Number Publication Date
WO2006027468A2 WO2006027468A2 (fr) 2006-03-16
WO2006027468A3 true WO2006027468A3 (fr) 2006-06-29

Family

ID=34948781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002152 Ceased WO2006027468A2 (fr) 2004-08-27 2005-08-26 Epitopes t cd4+ du vih restreints a hla-dp4 et leurs applications

Country Status (2)

Country Link
FR (1) FR2874612A1 (fr)
WO (1) WO2006027468A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
WO2007039458A2 (fr) * 2005-09-21 2007-04-12 Cytos Biotechnology Ag Conjugues peptidiques du vih et leurs utilisations
US20150175666A1 (en) * 2012-06-27 2015-06-25 Yeda Research And Development Co. Ltd. Peptides derived from hiv gp41 for treating t-cell mediated pathologies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A2 (fr) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
EP0339504A2 (fr) * 1988-04-26 1989-11-02 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
EP0572737A2 (fr) * 1992-06-04 1993-12-08 The Research Foundation For Microbial Diseases Of Osaka University Antigène fusion gag-env de HIV
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
WO2001024810A1 (fr) * 1999-10-05 2001-04-12 Epimmune Inc. Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques
WO2004108753A1 (fr) * 2003-06-10 2004-12-16 The University Of Melbourne Compositions immuno-modulatrices, leurs utilisations et leurs procedes de production

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US7195768B2 (en) * 2001-11-07 2007-03-27 Duke University Polyvalent immunogen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A2 (fr) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
EP0339504A2 (fr) * 1988-04-26 1989-11-02 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
EP0572737A2 (fr) * 1992-06-04 1993-12-08 The Research Foundation For Microbial Diseases Of Osaka University Antigène fusion gag-env de HIV
WO2001024810A1 (fr) * 1999-10-05 2001-04-12 Epimmune Inc. Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques
WO2004108753A1 (fr) * 2003-06-10 2004-12-16 The University Of Melbourne Compositions immuno-modulatrices, leurs utilisations et leurs procedes de production

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALTER G ET AL.: "Human Immunodeficiency Virus (HIV)-Specific Effector CD8 T Cell Activity in Patients with Primary HIV Infection", THE JOURNAL OF INFECTIOUS DISEASES, vol. 185, no. 6, 15 March 2002 (2002-03-15), pages 755 - 765, XP002372040 *
GAUSEPOHL H ET AL: "AUTOMATED MULTIPLE PEPTIDE SYNTHESIS", PEPTIDE RESEARCH, NATICK, MA, US, vol. 5, no. 6, 1992, pages 315 - 320, XP000775679, ISSN: 1040-5704 *

Also Published As

Publication number Publication date
WO2006027468A2 (fr) 2006-03-16
FR2874612A1 (fr) 2006-03-03

Similar Documents

Publication Publication Date Title
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
EP3266464A3 (fr) Thérapeutique à base de levure pour infection chronique par l'hépatite b
EP2280073A3 (fr) Vaccin pour la prévention et le traitement de l'infection par le VIH
WO2006041933A3 (fr) Vaccins ameliores
WO2007066334A9 (fr) Vaccin ameliore contre la grippe
WO2006082313A3 (fr) Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications
WO2010003691A3 (fr) Bioconjugués comprenant des déterminants antigéniques spécifiques d'auto-anticorps dirigés contre le peptide β-amyloïde utilisables pour une immunothérapie active, ainsi que pour le diagnostic de la maladie d'alzheimer
WO2006110831A3 (fr) Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine
WO2003015702A3 (fr) Epitopes du virus de l'immunodeficience humaine de type 1
WO2006027468A3 (fr) Epitopes t cd4+ du vih restreints a hla-dp4 et leurs applications
WO2018066999A3 (fr) Particules pseudo-virale d'entérovirus chimériques
WO2006050219A3 (fr) Anticorps monoclonaux humains a reaction antigenique croisee large neutralisant generalement vih-1
WO2009042538A3 (fr) Protéines immunogènes provenant d'une membrane extérieure dérivée du génome de leptospira et compositions et procédés à base de celles-ci
WO2007146359A3 (fr) Vaccins antigéniques du pou du poisson
WO2007123906A3 (fr) Antigènes recombinés pour le diagnostic et la prévention du typhus murin
WO2006007555A3 (fr) Antigenes de rotavirus
WO2005110492A3 (fr) Méthode pour utiliser les vecteurs adénovirals amener une réponse immunitaire
WO2006138745A3 (fr) Peptides et vaccins therapeutiques
WO2012050893A3 (fr) Polypeptides immunogènes ayant une protéine de structure immunogène et un peptide de boucle, présentant un épitope ciblé par un anticorps monoclonal 3074 ou 2219/2557, qui est présent dans la protéine gp120 du vih
WO2004018511A3 (fr) Composes peptidiques composites destines au diagnostic et au traitement de maladies induites par des proteines prions
WO2007026078A3 (fr) Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications
WO2005089231A3 (fr) Activite renforcee de vaccin vih utilisant un oligonucleotide immunomodulateur de seconde generation
WO2012058363A3 (fr) Protéine d'enveloppe recombinante du virus de l'immunodéficience humaine (vih) et vaccin la contenant
WO2002026785A3 (fr) Epitopes du virus de l'hepatite c specifiques des lymphocytes t cd4?+¿
WO2002069691A3 (fr) Peptides vih immunogenes utilises en tant que reactifs et en tant que vaccins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05798351

Country of ref document: EP

Kind code of ref document: A2